Fig. 2: Cumulative MIC distribution for antibiotics alone or combined with potentiators (38 µM PAβN, 2.5 µM NV731 and NV716) against clinical isolates. | Communications Biology

Fig. 2: Cumulative MIC distribution for antibiotics alone or combined with potentiators (38 µM PAβN, 2.5 µM NV731 and NV716) against clinical isolates.

From: The membrane-active polyaminoisoprenyl compound NV716 re-sensitizes Pseudomonas aeruginosa to antibiotics and reduces bacterial virulence

Fig. 2

The vertical dotted line shows the human Cmax values for each antibiotic75,76 (a doxycycline; b chloramphenicol; c rifampicin; d ciprofloxacin). The table e shows the proportion of isolates for which MICs are below this Cmax value, and thus falls in the range of therapeutically-achievable concentrations. All MICs were determined in at least 2-3 independent experiments (if values differing of 1–2 dilutions were obtained, the most frequent one was considered).

Back to article page